This study is being done to answer the following question: Can we extend your life after the diagnosis of your cancer in the stomach, esophagus, or gastroesophageal junction by adding a third chemotherapy drug to the usual combination of two chemotherapy drugs? We are doing this study because we want to find out if this approach is better or worse than the usual approach for treatment of your cancer in the stomach, esophagus, or gastroesophageal junction. The usual approach is defined as care most people get for cancer in the stomach, esophagus, or gastroesophageal junction.

Do you have Stage II or III Breast cancer? If you have enough tissue from your breast cancer diagnosis to send for Mammaprint genomic testing, you may be able to take part in this research study. In this study, we want to learn more about adding an immunotherapy drug, durvalumab, to your chemotherapy treatment. The Mammaprint testing is conducted at no cost to you and the cost of durvalumab is covered.

In this study, we want to determine if dietary intervention is feasible for patients being treated for leukemia or lymphoma.

This is a study to test the dosing and safety of the drug AB248 for people who have an advanced melanoma tumors and who have previously received systemic therapy.

In this study, we want to find out if a combination of 3 different study drugs (Cabozantinib, Ipilimumab, and Nivolumab) will affect the progression of Soft Tissue Sarcoma.

Do you have intermediate risk prostate cancer and don't want to undergo surgery? You may be able to participate in a research study comparing therapy based on genetic testing.

The main purpose of the study is to determine whether the study drug, ONC-392, together with a standard of care drug PLUVICTO® (Lutetium Lu 177 Vipivotide Tetraxetan), are safe and well tolerated, and whether two drugs are effective in treating prostate cancer, in comparison with the standard of care PLUVICTO® alone.

The purpose of this study is to learn about the effects of a research investigational product, CT-0525, and to see if CT-0525 is safe for participants with advanced cancer. This study is the first time that CT-0525 will be given to humans. CT-0525 is a special kind of product that is made of blood cells taken from your own body. Once collected, these blood cells will be altered and infused back into your body.

Primary Objective: Demonstrate the superiority of belumosudil in combination with prednisone vs placebo in combination with prednisone in Event-Free Survival (EFS) Secondary Objective:Demonstrate the superiority of belumosudil in combination with prednisone vs placebo incombination with prednisone in modified Lee Symptom Scale (mLSS) improvement,overall ,response rate (ORR) and in the rate of corticosteroid withdrawal

To study the effect of adding chemotherapy given after breast surgery with aromatase inhibitor and ovarian suppression versus ovarian suppression and endocrine therapy alone, in premenopausal patients with ER-positive, HER2-negative breast cancer.